Researchers question the generalizability of a major study showing no significant difference in cancer-specific and overall survival between surgery and observation for localized prostate cancer.

WARREN, N.J., May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease ...